Navigation Links
Sangamo Announces Pricing of Public Offering of Common Stock
Date:4/8/2011

RICHMOND, Calif., April 8, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the pricing of its previously announced public offering of 6,700,000 shares of its common stock at a price to the public of $7.70 per share.  The public offering is expected to close on or around Wednesday, April 13, 2011, subject to customary closing conditions. Barclays Capital Inc. is the sole book-running manager in this offering and Sangamo has granted the underwriter a thirty (30) day option to purchase up to 1,005,000 additional shares.

The securities described above are being offered by Sangamo pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on June 16, 2009. Copies of the prospectus supplement and the related prospectus, when available, may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; Barclaysprospectus@broadridge.com (phone: 888-603-5847).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... DUBLIN , July 31, 2014 ... the "Global Genomics Market 2014-2018" report to ... Genomics is the study of the genetic ... to be a strong basis for the discovery and ... of human diseases or health conditions. Genomics is supported ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 ... a leading company using proprietary taste science technologies ... for the food, beverage, and ingredient supply industries, ... 2014.  The Company ended the second quarter with ... "During the past quarter Senomyx ...
(Date:7/31/2014)... SAN DIEGO and SHENZHEN, China ... Genomics announced today the purchase of an ... genomics organization. BGI selected BioNano,s platform to enable comprehensive ... vastly improved assemblies for various organisms of interest, including ... BGI will partner together to develop new methods for ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Rancho ... the integration of Omicsoft’s Array Suite with tranSMART ... will be able to send data in tranSMART to ... with all versions of tranSMART including the new 1.2 ... statistics, visualization and storage for the analysis of high ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3
... M2S Expert Dr. Steven Marra will give the ... Sigma in the Imaging Core Lab" at the ... for Clinical Trials conference. Dr. Marra,s presentation will ... principles have contributed to the development of the ...
... -- Pharmaceutical company Pharmaxis,(ASX: PXS; Nasdaq: PXSL ... Fox,to its senior management team in the position of ... regulatory affairs, pharmacovigilance and,medical affairs. Clinical Operations will ... , Dr Fox has more ...
... journal, Science, reports that advanced cholesterol test aids in ... BIRMINGHAM, Ala., Feb. 16 ... University of Maryland researchers have found an association ... information reported in a recent study could help in ...
Cached Biology Technology:M2S Expert gives address "Applying the Principles of Six Sigma in the Imaging Core Lab" at Imaging for Clinical Trials conference 2Pharmaxis Builds Senior Management Team 2VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 2VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 3VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 4
(Date:7/31/2014)... long-term follow-up study (HPV-023; NCT00518336) shows the ... human papilloma virus (HPV) vaccine Cervarix. Women ... followed for more than nine years, and ... 100%. This is the longest follow-up report ... https://www.landesbioscience.com/journals/vaccines/article/29532/ for the full paper. , ...
(Date:7/31/2014)... in German . ... similar to a sponge that soaks up liquids. Hence, ... or greenhouse gases. However, loading of many MOFs is ... (KIT) now report in Nature Communications that ... surface. This can be prevented by water-free synthesis and ...
(Date:7/31/2014)... effect in 1839, humankind has sought to further understand ... purposes. In a new research report published in the ... , scientists may have uncovered a new method ... a naturally occurring combination of lipids that have been ... and across speciessuggests that this specific natural combination of ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3Free pores for molecule transport 2Scientists shine bright new light on how living things capture energy from the sun 2
... believes that changes in behaviour among the population have accelerated ... Research published today in Science shows how there has been ... groups, which the researchers attribute to people delaying when they ... found HIV prevalence fell most steeply at young ages, with ...
... venom could provide the next generation of human therapeutic ... been identified by Queensland University of Technology PhD researcher ... vascular surgery and major trauma. , The genetic code ... by PhD researcher Liam St Pierre from QUT's School ...
... a case of evolutionary detective work. Biology researchers at ... have found evidence for an ancient transfer of a ... a bacterium. But the mystery remains as how the ... published this month in the journal Bioinformatics, 22(3): 264-268, ...
Cached Biology News:HIV decline in Zimbabwe linked to behavioural change 2Taipan venom no snake oil 2Evolution mystery: Spider venom and bacteria share same toxin 2
... highly versatile power supply. Capable of producing up ... supply is ideal for PAGE, SDS-PAGE, DNA or ... of small format transfer apparatus. It is designed ... with a continuously variable output in either mode. ...
... supply is a highly compact, extremely reliable and ... knob and one hi-lo range switch control the ... from 20 to 250 volts. One two-position switch ... voltage to output current. For maximum safety, the ...
... a recombinant 177 amino acid polypeptide sequence ... human MT1-MMP. Produced by activation of ... from E. coli periplasm. SPECIFIC ACTIVITY:The ... = 140 mU/mg, where 1 U is ...
... mM sodium phosphate buffer, pH 6.5. Cathepsin ... a major lysosomal aspartyl protease in mammalian ... Overexpression of cathepsin D in human breast ... relapse and metastasis. Cathepsin D degrades extracellular ...
Biology Products: